Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019;74(1):112–34. https://doi.org/10.1111/his.13734.

Article  PubMed  Google Scholar 

von der Maase H, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. https://doi.org/10.1200/JCO.2005.07.757.

Article  CAS  PubMed  Google Scholar 

De Santis M, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9. https://doi.org/10.1200/JCO.2011.37.3571.

Article  CAS  PubMed  Google Scholar 

Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83. https://doi.org/10.1093/annonc/mdx686.

Article  CAS  PubMed  Google Scholar 

Plimack ER, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212–20. https://doi.org/10.1016/S1470-2045(17)30007-4.

Article  CAS  PubMed  Google Scholar 

Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanli O, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3(1):17022. https://doi.org/10.1038/nrdp.2017.22.

Article  PubMed  Google Scholar 

Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol. 2018;15(2):112–24. https://doi.org/10.1038/nrurol.2017.190.

Article  CAS  PubMed  Google Scholar 

Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57. https://doi.org/10.1016/S0140-6736(17)33297-X.

Article  CAS  PubMed  Google Scholar 

Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease: Trends in Immunology. https://www.cell.com/trends/immunology/fulltext/S1471-4906(13)00110-5?script=true. Accessed 07 Aug 2022

Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Natsugoe S. Clinical significance of the B7–H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 2011;35(9):2051–7. https://doi.org/10.1007/s00268-011-1186-4.

Article  PubMed  Google Scholar 

Sun S-Q, Jiang C-G, Lin Y, Jin Y-L, Huang P-L. Enhanced T cell immunity by B7–H4 downregulation in nonsmall-cell lung cancer cell lines. J Int Med Res. 2012;40(2):497–506. https://doi.org/10.1177/147323001204000211.

Article  CAS  PubMed  Google Scholar 

Cheng L, et al. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer. 2009;19(9):1481–6. https://doi.org/10.1111/IGC.0b013e3181ad0fa2.

Article  PubMed  Google Scholar 

Sachdev JC, et al. Phase 1a/1b study of first-in-class B7–H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. JCO. 2019;37(15):2529–2529. https://doi.org/10.1200/JCO.2019.37.15_suppl.2529.

Article  Google Scholar 

Meric-Bernstam F, et al. First-in-human study of the B7–H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. JCO. 2022;40(16):TPS3153–TPS3153. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS3153.

Article  Google Scholar 

Li J, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity. 2018;48(4):773-786.e5. https://doi.org/10.1016/j.immuni.2018.03.018.

Article  CAS  PubMed  Google Scholar 

Singh A, et al. Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of urothelial carcinoma of bladder. Mol Cell Biochem. 2021. https://doi.org/10.1007/s11010-021-04299-8.

Article  PubMed  PubMed Central  Google Scholar 

Anand V, et al. CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach. J Cancer Res Clin Oncol. 2019;145(11):2649–61. https://doi.org/10.1007/s00432-019-03024-9.

Article  PubMed  Google Scholar 

Khandelwal M, et al. RASSF1A–Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target. Mol Cell Biochem. 2020;464(1–2):51–63. https://doi.org/10.1007/s11010-019-03648-y.

Article  CAS  PubMed  Google Scholar 

Chugh S, Anand V, Swaroop L, Sharma M, Seth A, Sharma A. Involvement of Th17 cells in patients of urothelial carcinoma of bladder. Hum Immunol. 2013;74(10):1258–62. https://doi.org/10.1016/j.humimm.2013.06.032.

Article  CAS  PubMed  Google Scholar 

Satyam A, Singh P, Badjatia N, Seth A, Sharma A. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol. 2011;29(1):58–65. https://doi.org/10.1016/j.urolonc.2009.06.002.

Article  CAS  PubMed  Google Scholar 

Qian Y, et al. Development of a novel monoclonal antibody to B7–H4: characterization and biological activity. Eur J Med Res. 2011;16(7):295–302. https://doi.org/10.1186/2047-783X-16-7-295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang T, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7(45):73068–79. https://doi.org/10.18632/oncotarget.12230.

Article  PubMed  PubMed Central  Google Scholar 

Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105(39):15016–21. https://doi.org/10.1073/pnas.0801497105.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Wang B, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110(2):489–98. https://doi.org/10.1111/cas.13887.

Article  CAS  PubMed  Google Scholar 

Ding X, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Cancer Manag Res. 2019;11:4171–84. https://doi.org/10.2147/CMAR.S176937.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsunaga T, Saito H, Ikeguchi M. Increased B7–H1 and B7–H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer. Yonago Acta Med. 2011;54(1):1–10.

PubMed  PubMed Central  Google Scholar 

Smith JB, Stashwick C, Powell DJ. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014;134(1):181–9. https://doi.org/10.1016/j.ygyno.2014.03.553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arrieta O, et al. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget. 2017;8(60):101994–2005. https://doi.org/10.18632/oncotarget.22025.

Article  PubMed  PubMed Central  Google Scholar 

Fan M, et al. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int J Clin Exp Pathol. 2014;7(10):6768–75.

PubMed  PubMed Central  Google Scholar 

Ding S, et al. Overexpression of B7–H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer. Int Immunopharmacol. 2021;90:107144. https://doi.org/10.1016/j.intimp.2020.107144.

Article  CAS  PubMed  Google Scholar 

Tringler B, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100(1):44–52. https://doi.org/10.1016/j.ygyno.2005.08.060.

Article  CAS  PubMed  Google Scholar 

Zang X, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104(49):19458–63. https://doi.org/10.1073/pnas.0709802104.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Liu W-H, et al. B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms. Oncol Lett. 2014;8(6):2527–34.